Edesa Biotech, Inc. (EDSA)
4.01
-0.02
(-0.50%)
USD |
NASDAQ |
Sep 25, 16:00
4.05
+0.04
(+1.00%)
After-Hours: 19:59
Edesa Biotech Enterprise Value : 36.71M for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 36.71M |
| September 24, 2026 | 36.90M |
| September 23, 2026 | 36.32M |
| September 22, 2026 | 37.29M |
| September 21, 2026 | 37.67M |
| September 18, 2026 | 37.96M |
| September 17, 2026 | 37.96M |
| September 16, 2026 | 35.36M |
| September 15, 2026 | 37.77M |
| September 14, 2026 | 37.91M |
| September 11, 2026 | 38.83M |
| September 10, 2026 | 42.97M |
| September 09, 2026 | 43.55M |
| September 08, 2026 | 43.64M |
| September 04, 2026 | 43.64M |
| September 03, 2026 | 43.93M |
| September 02, 2026 | 43.93M |
| September 01, 2026 | 44.13M |
| August 31, 2026 | 43.69M |
| August 28, 2026 | 42.59M |
| August 27, 2026 | 42.39M |
| August 26, 2026 | 45.67M |
| August 25, 2026 | 40.95M |
| August 24, 2026 | 40.47M |
| August 21, 2026 | 40.75M |
| Date | Value |
|---|---|
| August 20, 2026 | 43.93M |
| August 19, 2026 | 53.47M |
| August 18, 2026 | 53.09M |
| August 17, 2026 | 52.51M |
| August 14, 2026 | 49.62M |
| August 13, 2026 | 50.39M |
| August 12, 2026 | 49.14M |
| August 11, 2026 | 51.26M |
| August 10, 2026 | 48.56M |
| August 07, 2026 | 48.85M |
| August 06, 2026 | 46.73M |
| August 05, 2026 | 47.88M |
| August 04, 2026 | 49.71M |
| August 03, 2026 | 48.46M |
| July 31, 2026 | 47.31M |
| July 30, 2026 | 48.65M |
| July 29, 2026 | 49.71M |
| July 28, 2026 | 45.96M |
| July 27, 2026 | 49.62M |
| July 24, 2026 | 48.65M |
| July 23, 2026 | 52.60M |
| July 22, 2026 | 52.80M |
| July 21, 2026 | 56.17M |
| July 20, 2026 | 54.14M |
| July 17, 2026 | 61.66M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ProMIS Neurosciences, Inc. | 47.60M |
| Arrowhead Pharmaceuticals, Inc. | 9.078B |
| Oncolytics Biotech, Inc. | 81.50M |
| Sangamo Therapeutics, Inc. | 51.40M |
| Sarepta Therapeutics, Inc. | 2.229B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.408M |
| Total Expenses (Quarterly) | 5.408M |
| EPS Diluted (Quarterly) | -0.6003 |
| Earnings Yield | -42.19% |
| Normalized Earnings Yield | -43.37 |